• Inventors:
  • Assignees:
  • Publication Date: December 31, 1969
  • Publication Number:

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (0)

    Title

Cited By (86)

    Publication numberPublication dateAssigneeTitle
    WO-2006090291-A2August 31, 2006Fondazione Centro San Raffaele Del Monte Tabor, Fondazione TelethonMethod for expanding cd4+ cd25+ t regulatory cells
    WO-2015121795-A1August 20, 2015Novartis AgCombinaisons pharmaceutiques comprenant un inhibiteur de pi3k permettant le traitement du cancer
    US-8618141-B2December 31, 2013Bayer Healthcare LlcAryl ureas with angiogenesis inhibiting activity
    US-7625726-B2December 01, 2009WyethProcess for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    US-7897623-B2March 01, 2011Bayer Healthcare Llcω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
    US-2005239178-A1October 27, 2005WyethLabeling of rapamycin using rapamycin-specific methylases
    US-7445916-B2November 04, 2008WyethProcess for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    US-9439912-B2September 13, 2016University Of Maryland, BaltimoreAndrogen receptor down-regulating agents and uses thereof
    US-5912253-AJune 15, 1999Novartis AgRapamycin derivatives
    WO-2012148846-A1November 01, 2012Novartis AgCombination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
    US-2009029426-A1January 29, 2009WyethProcess for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    US-8796250-B2August 05, 2014Bayer Healthcare LlcDiaryl ureas for diseases mediated by PDGFR
    US-9387216-B2July 12, 2016Tokai Pharmaceuticals, Inc., University Of Washington, University Of Maryland, BaltimoreBiomarkers for treatment of neoplastic disorders using androgen-targeted therapies
    WO-2017029391-A1February 23, 2017INSERM (Institut National de la Santé et de la Recherche Médicale), Université D'aix Marseille, Institut Jean Paoli & Irene Calmettes, Centre National De La Recherche Scientifique (Cnrs)Nouvelle méthode de traitement du cancer
    US-9526723-B2December 27, 2016The University Of ChicagoTreatment with opioid antagonists and mTOR inhibitors
    US-8236048-B2August 07, 2012Cordis Corporation, WyethDrug/drug delivery systems for the prevention and treatment of vascular disease
    US-6200985-B1March 13, 2001Novartis AgRapamycin derivatives
    WO-9504060-A1February 09, 1995Smithkline Beecham PlcDerive de la rapamycine ayant une activite antimicrobienne, anticancereuse et immunomodulatrice
    US-5563146-AOctober 08, 1996American Home Products CorporationMethod of treating hyperproliferative vascular disease
    US-2010279364-A1November 04, 2010WyethCCI-779 derivatives and methods of making same
    US-8685995-B2April 01, 2014The University Of ChicagoTreatment with opioid antagonists and mTOR inhibitors
    US-6399625-B1June 04, 2002Wyeth1-oxorapamycins
    US-5985890-ANovember 16, 1999Novartis AgRapamycin derivatives
    US-9101609-B2August 11, 2015Emergent Product Development Seattle, LlcCD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
    US-2009012298-A1January 08, 2009Murat Acemoglu, Sabine PfefferProcess for the Preparation of Rapamycin Derivatives
    WO-2007085400-A1August 02, 2007Novartis AgProcess for the preparation of rapamycin derivatives
    US-2005234087-A1October 20, 2005WyethProcess for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    EP-0781776-A2July 02, 1997American Home Products CorporationEsters de la rapamycine hydrosolubles
    US-9359395-B2June 07, 2016Tokai Pharmaceuticals, Inc.Prodrugs of steroidal CYP17 inhibitors/antiandrogens
    US-8790391-B2July 29, 2014Cordis CorporationMethods and devices for delivering therapeutic agents to target vessels
    US-5516781-AMay 14, 1996American Home Products CorporationMethod of treating restenosis with rapamycin
    EP-3106164-A1December 21, 2016Wyeth LLCAntitumorwirkung von temsirolimus bei papillärem nierenzellkarzinom
    US-8562974-B2October 22, 2013Fondazione Telethon, Ospedale San Raffaele S.R.L.Method for expanding Cd4+ Cd25+ T regulator cells
    US-6432973-B1August 13, 2002WyethWater soluble rapamycin esters
    WO-2011130232-A1October 20, 2011Novartis AgCombination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
    US-5646160-AJuly 08, 1997American Home Products CorporationMethod of treating hyperproliferative vascular disease with rapamycin and mycophenolic acid
    US-5672605-ASeptember 30, 1997Abbott LaboratoriesMacrolide immunomodulators
    US-2008014614-A1January 17, 2008WyethLabeling of rapamycin using rapamycin-specific methylases
    US-8303609-B2November 06, 2012Cordis Corporation, WyethCoated medical devices
    US-2010285089-A1November 11, 2010Llanos Gerard H, Roller Mark B, Angelo George Scopelianos, Robert FaloticoMedical Devices, Drug Coatings And Methods For Maintaining The Drug Coatings Thereon
    US-8242147-B2August 14, 2012Bayer Healthcare LlcAryl ureas with angiogenisis inhibiting activity
    US-8138344-B2March 20, 2012Novartis AgProcess for the preparation of rapamycin derivatives
    US-5527907-AJune 18, 1996Abbott LaboratoriesMacrolide immunomodulators
    EP-2253320-A1November 24, 2010Novartis AGAssociation d'un pyrimidylaminobenzamide et d'un inhibiteur de la mTOR kinase
    US-2011060265-A1March 10, 2011Wyeth LlcImplantable shunt or catheter enabling gradual delivery of therapeutic agents
    US-5583139-ADecember 10, 1996Abbott LaboratoriesMarcolide immunomodulators
    EP-1767193-A2March 28, 2007Novartis AG, Novartis Pharma GmbHPharmazeutische Zusammensetzungen
    US-8076488-B2December 13, 2011Bayer Healthcare LlcBicyclic urea derivatives useful in the treatment of cancer and other disorders
    US-8124630-B2February 28, 2012Bayer Healthcare Llcω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
    US-6511986-B2January 28, 2003WyethMethod of treating estrogen receptor positive carcinoma
    WO-2013192367-A1December 27, 2013Novartis AgNeuroendocrine tumor treatment
    US-8299116-B2October 30, 2012Wyeth LlcCCI-779 concentrate formulations
    US-8853366-B2October 07, 2014Emergent Product Development Seattle, LlcBinding domain-immunoglobulin fusion proteins
    WO-2015171723-A1November 12, 2015Research Development FoundationMéthodes pour traiter la résistance à l'insuline et pour sensibiliser des patients à un traitement avec un agoniste du glp1
    US-2006058399-A1March 16, 2006Michael Ambuhl, Barbara Luckel, Friedrich Richter, Barbara Haberlin, Armin MeinzerEmulsion preconcentrates containing cyclosporin or a macrolide
    EP-0734389-B1March 29, 2000Novartis AG, Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.Rapamycin-derivate als immunosuppressoren
    US-7591844-B2September 22, 2009Cordis Corporation, WyethMedical devices, drug coatings and methods for maintaining the drug coatings thereon
    US-8455539-B2June 04, 2013Wyeth LlcCCI-779 concentrate formulations
    US-2009305236-A1December 10, 2009Genetic Technologies LimitedMethods of enriching fetal cells
    US-5665728-ASeptember 09, 1997American Home Products CorporationMethod of treating hyperproliferative vascular disease
    RU-2448970-C2April 27, 2012Новартис АгСпособ получения производных рапамицина
    US-7528145-B2May 05, 2009WyethUse of an mTOR inhibitor in treatment of uterine leiomyoma
    US-5712129-AJanuary 27, 1998Smithkline Beecham P. L. C.Rapamycin derivative with antimicrobial, anticancer and immunomodulation activity
    US-2008051865-A1February 28, 2008Llanos Gerard H, Roller Mark B, Scopelianos Angelo GMedical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
    US-9808472-B2November 07, 2017Tokai Pharmaceuticals, Inc., University Of Washington, University Of Maryland, BaltimoreBiomarkers for treatment of neoplastic disorders using androgen-targeted therapies
    US-2008317827-A1December 25, 2008Cordis CorporationMethods and Devices for Delivering Therapeutic Agents to Target Vessels
    US-9884067-B2February 06, 2018University Of Maryland, Baltimore, University Of Maryland Eastern Shore, Thomas Jefferson UniversityAndrogen receptor down-regulating agents and uses thereof
    WO-2012171882-A1December 20, 2012Hans-Dieter Volk, Schmueck Michael, Petra ReinkeAntigen-specific central-memory t cell preparations having high cd4+ fraction
    US-8637553-B2January 28, 2014Bayer Healthcare LlcFluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
    WO-2011128405-A1October 20, 2011Novartis AgCombinaison de composés organiques
    EP-2583678-A2April 24, 2013Novartis Vaccines and Diagnostics, Inc.Immunstimulatoren kleiner Moleküle und Assays für deren Nachweis
    US-2006094745-A1May 04, 2006WyethUse of an mTOR inhibitor in treatment of uterine leiomyoma
    WO-2011109833-A2September 09, 2011President And Fellows Of Harvard CollegeInduced dendritic cell compositions and uses thereof
    US-8026276-B2September 27, 2011Wyeth LlcParenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
    US-7332601-B2February 19, 2008WyethCCI-779 derivatives and methods of making same
    US-2011152201-A1June 23, 2011Ambuehl Michael, Lueckel Barbara, Friedrich Richter, Haeberlin Barbara, Armin MeinzerEmulsion preconcentrates containing cyclosporin or a macrolide
    US-2006036091-A1February 16, 2006WyethCCI-779 derivatives and methods of making same
    WO-2014068070-A1May 08, 2014INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for preventing antiphospholipid syndrome (aps)
    EP-2532740-A1December 12, 2012Michael Schmück, Petra Reinke, Hans-Dieter VolkPréparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
    US-2003216303-A1November 20, 2003Michael Ambuhl, Barbara Luckel, Friedrich Richter, Barbara Haberlin, Armin MeinzerEmulsion preconcentrates containing cyclosporin or a macrolide
    US-2008279826-A1November 13, 2008Fondazione Centro San Rafaele Del Monte Tabor, Fondazione TelethonMethod for Expanding Cd4+ Cd25+ T Regulator Cells
    EP-2039358-A1March 25, 2009Novartis AG, Novartis-Pharma GmbhPharmazeutische Zusammensetzungen enthaltend einen Makrolide und eine Säure
    US-2004167152-A1August 26, 2004WyethParenteral formulations
    US-8841330-B2September 23, 2014Bayer Healthcare LlcOmega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
    US-8722700-B2May 13, 2014Wyeth LlcCCI-779 formulations for parenteral administration
    WO-2006038972-A1April 13, 2006WyethDerives du cci-779 et procedes pour les fabriquer